Pipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpoints

Ironwood Pharmaceuticals’s apraglutide saw its Likelihood of Approval (LoA) rise in short bowel syndrome (SBS) after a Phase III trial in the same indication reached its endpoints.